BridgeBio Pharma (BBIO) PT Raised to $70 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $70.00 (from $56.00) while maintaining a Buy rating.

The analyst commented: "We draw investors' attention to the fact that ATTRUBY (acoramidis) sales in the U.S. continue to beat expectations. In 2Q25, the product generated $71.5M in net sales, handily beating our original estimate of $56.2M. We currently believe that acoramidis sales could reach $324.5M vs. our prior estimate of only $280.3M; for 2026, we are now projecting otal acoramidis net sales of $739.5M vs. our previous estimate of only $609.2M. From our vantage point, acoramidis looks well-established as a best-in-class TTR stabilizer and we expect the drug to continue to show strength on the new and repeat Rx front as well as with respect to the prescriber base. Additional open-label data on acoramidis from the ATTRIBUTE-CM program are being presented this weekend during the European Society of Cardiology (ESC) Congress taking place in Madrid, Spain. We reiterate our Buy rating, while raising our 12-month price target to $70 from $56. We also point out for investors the following key near-term catalysts and recent favorable developments: (1) the NASDAQ listing of BridgeBio Oncology Therapeutics (BBOT; not rated), which went public earlier this month via merger with Helix Acquisition Corp. II, a special purpose acquisition company (SPAC) sponsored by affiliates of Cormorant Asset Management, with $382M in total funding (we remind investors that BridgeBio Pharma retains ownership of roughly 17.5% of BBOT); (2) upcoming top-line data from the FORTIFY trial of BBP-418 (ribitol) in limb-girdle muscular dystrophy (LGMD2i/R9) in the coming months; and (3) top-line data from CALIBRATE, the pivotal Phase 3 study of encaleret (a calcium-sensing receptor inhibitor) for autosomal dominant hypocalcemia type 1 (ADH1), in fall 2025—approximately 95% of randomized study participants have already entered the long-term extension of the study."

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)